Abstract
Over the last years there has been a growing interest in the use of antibodies and antibody fragments as therapeutic entities to treat cancer. Identification of the smallest antibody fragment still capable of binding to antigen has progressed from full antibody molecules to Fab and recombinant single chain Fv fragments. A further reduction to single-domain binding proteins based upon immuno-globulin VH and VH-like domains is being pursued since they offer exciting prospects in the development of novel immunotherapeutics. Unfortunately, the poor solubility and reduced antigen affinity requires additional engineering. By serendipity, it was discovered that this engineering is already performed in nature. Part of the humoral immune response of camels and llamas is based largely on heavy-chain antibodies where the light chain is totally absent. These unique antibody isotypes interact with the antigen by virtue of only one single variable domain, referred to as VHH. Here we describe the properties of camel VHH that offer added value over conventional antibody fragments as treatment modality for tumour patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hamers, C., Bayjana Songa, E., Bendahman, N. and Hamers, R. (1993) Nature 363, 446–448.
Gharhoudi, M., Desmyter, A., Wyns, L., Hamers, R. and Muyldermans, S. (1997) FEBS Lett. 414, 521–526.
Lauwereys, M., Gharhoudi, M., Desmyter, A., Kine, J., Holzer, W., De Genst, E., Wyns, L. and Muyldermans, S. (1998) EMBO J. 17, 3512–3520.
Muruganandam, A., Tanha, J., Narang, S. nd Stanimirovic, D (2002) FASEB J. 16, 240–242.
Cortez-Retamozo, V., Lauwereys, M., Hassanzadeh, G. G., Gobert, M., Conrath, K., Muyldermans, S., De Baetselier, P., and Revets, H. (2002) Int. J. Cancer 98, 456–462.
Visintin, M., Settanni, G., Maritan, A., Graziosi, S., Marks, JD. and Cattaneo, A. (2002) J. Mol. Biol. 317, 73–83
Author information
Authors and Affiliations
Editor information
Rights and permissions
Copyright information
© 2005 Springer
About this paper
Cite this paper
Cortez-Retamozo, V. et al. (2005). Camel Single-Domain Antibodies as Modular Building Blocks to Make Bivalent Constructs for Use in Immunotherapy of Cancer. In: Gòdia, F., Fussenegger, M. (eds) Animal Cell Technology Meets Genomics. ESACT Proceedings, vol 2. Springer, Dordrecht. https://doi.org/10.1007/1-4020-3103-3_95
Download citation
DOI: https://doi.org/10.1007/1-4020-3103-3_95
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-2791-8
Online ISBN: 978-1-4020-3103-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)